New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
ÌÇÐÄ´«Ã½
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy ONCOIMMUNOLOGY Garcia-Martinez, E., Smith, M., Buque, A., Aranda, F., Ayala de la Pena, F., Ivars, A., Sanchez Canovas, M., Vicente Conesa, M., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L. 2018; 7 (6): e1433982Abstract
Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-a2a and IFN-a2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-a2a and IFN-a2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, ÌÇÐÄ´«Ã½ in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize ÌÇÐÄ´«Ã½ preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients.
View details for
View details for
View details for
View details for